1-4 of 4
T. Fischer, MD
Close
Sort by
Journal Articles

Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL.

C. Gambacorti-Passerini, MD, H. Kantarjian, MD, T. Bruemmendorf, MD, G. Martinelli, MD, M. Baccarani, MD, T. Fischer, MD, E.M. Pogliani, MD, B. Hewes, MD, A.D.G. Volkert, MD, N. Bardy-Bouxin, MD, J. Cortes, MD
Journal: Blood
Blood (2007) 110 (11): 473.
https://doi.org/10.1182/blood.V110.11.473.473
Published: 2007
Journal Articles

Efficacy and Safety of Bosutinib (SKI-606) among Patients with Chronic Phase Ph+ Chronic Myelogenous Leukemia (CML).

J. Cortes, MD, T. Bruemmendorf, MD, H. Kantarjian, MD, J. Khoury, MD, G. Rosti, MD, T. Fischer, MD, L. Tornaghi, MD, B. Hewes, MD, E.C. Martin, MD, C. Gambacorti-Passerini, MD
Journal: Blood
Blood (2007) 110 (11): 733.
https://doi.org/10.1182/blood.V110.11.733.733
Published: 2007
Journal Articles

Safety and Efficacy of a Combination of Imatinib and Pegylated Interferon α2a (Pegasys®) in Newly Diagnosed Patients with Chronic Myelogenous Leukemia - A Phase II Cohort Study.

Andreas Hochhaus, MD, A. Neubauer, MD, M.C. Mueller, MD, T. Fischer, MD, C. Waller, MD, T.H. Bruemmendorf, MD, T. Bostel, C. Lengerke, MD, R. Hehlmann, MD, A. Burchert, MD
Journal: Blood
Blood (2007) 110 (11): 1027.
https://doi.org/10.1182/blood.V110.11.1027.1027
Published: 2007
Journal Articles

Results of a Multicenter Phase II Trial for Older Patients with c-Kit Positive Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Using Low-Dose Ara-C (LDAC) and Imatinib.

F. Heidel, MD, J. Cortes, MD, F. Ruecker, MD, M. Kaufmann, MD, W. Aulitzky, MD, L. Letvak, MD, T. Kindler, MD, C. Huber, MD, H. Dohner, MD, H. Kantarjian, MD, T. Fischer, MD
Journal: Blood
Blood (2005) 106 (11): 1853.
https://doi.org/10.1182/blood.V106.11.1853.1853
Published: 2005